These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Search MEDLINE/PubMed
Title: [Monoamine imbalance of the central nervous system in a case of Shy-Drager syndrome with recurrent attacks of a neuroleptic malignant syndrome]. Author: Ueda M, Hamamoto M, Otsubo K, Miyazaki T, Terashi A. Journal: Rinsho Shinkeigaku; 1996 May; 36(5):696-8. PubMed ID: 8905993. Abstract: A 79-year-old male suffering from Shy-Drager syndrome was treated with a daily dosage of 300 mg of L-threo-3,4-dihydroxyphenylserine (L-DOPS). He developed a neuroleptic malignant syndrome (NMS) like state 1 month after teh initiation of L-DOPS therapy. And recurrent attacks of NMS occurred subsequently despite discontinuation of L-DOPS administration. We measured homovanillic acid (HVA), 3 methoxy 4 hydroxyphenylethylenglycol (MHPG), and 5-hydroxyindoleacetic acid (5-HIAA) in this corrected brospinal fluid (CSF), both during his 2 attacks of NMS and after recovery. The HVA and 5 HIAA levels after recovery were low compared with those in age-matched normal controls. However, his levels in the active phase were not different from those after recovery. In contrast, MHPG levels were elevated and his HVA/MHPG ratios decreased in the active phase compared with those in the recovery phase. The results indicate that his symptoms of NMS are attributed to the imbalance between dopamine and noradrenalin rather than the dopamine receptor blockade in the central nervous system. We suggest further evaluations of CSF monoamine metabolites in similar cases to determine the pathogenesis of NMS.[Abstract] [Full Text] [Related] [New Search]